Supplementary Data 1 from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Zhi Peng(Qingdao University), Lin Shen(Peking University), Jianjun Zou(Jiangsu Hengrui Medicine (China)), Feng Wang, Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanfei Tai(Jiangsu Hengrui Medicine (China)), Ying Cheng(Jilin Province Tumor Hospital), Yanhong Deng(Sun Yat-sen University), Yanqiao Zhang(Harbin Medical University), Wei Jia(Sichuan University), Linna Wang, Kangsheng Gu(Anhui Medical University), Xianglin Yuan(Tongji Hospital), Juxiang Xiao(First Affiliated Hospital of Xi'an Jiaotong University)
Unknown
March 31, 2023
10.1158/1078-0432.22479047.v1
Cited by 0

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k